We have also reported that the expression of costimulatory ligands CD80 and 4-1BBL on murine CD4 T-cells prolonged their longevity in vitro and in vivo, indicating their potential for use as alternative APCs for cancer immunotherapy [12]. This evidence concerns the gene CD80 and cancer.